PFE logo

Pfizer Inc.

PFE
Healthcare|Drug Manufacturers - General|US
$29.39
-0.06 (-0.20%)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50

About

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Stock Price

+18.3%(1Y)
1M
+5.6%
3M
+9.8%
6M
+14.4%
YTD
+18.0%
1Y
+20.5%
3Y
-4.6%
5Y
-39.2%

Pipeline Summary

941 total trials
265
Phase 1
179
Phase 2
233
Phase 3
138
Phase 4
Completed: 685Terminated: 129Recruiting: 38Withdrawn: 30Active: 41No Longer Available: 4Unknown: 8Not Yet Recruiting: 5By Invitation: 1

Active Trials (79)

Headache Ear Auditory Dizziness Sinus (HEADS) Registry
NCT07754266Headache Disorders
Recruiting
Enrollment: 10,000 participants
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms
Phase 2Active
Enrollment: 350 participants
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
NCT05198245Migraine
Active
Enrollment: 1 participants
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847Myelodysplastic Syndrome
Phase 1Active
Enrollment: 170 participants
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung
Phase 1Recruiting
Enrollment: 1,006 participants

BioScore

6.8/10
Buy

Key Facts

Market Cap$167.51B
Employees75,000 (-7% YoY)
CEOAlbert Bourla
IPO DateJun 1, 1972
Beta0.28
52-Week Range$23.62 – $31.44
Avg Volume36,193,051
ExchangeNYSE
Websitepfizer.com

Ownership

Float99.9%
Shares Outstanding5699.7M

Recent Insider Trades

BOURLA ALBERTAWARD
Oct 30, 202620 shares
BOURLA ALBERTAWARD
Oct 15, 202620 shares
BOURLA ALBERTAWARD
Oct 13, 202671 shares
BOURLA ALBERTAWARD
Sep 30, 202621 shares
Buckley Mortimer JAWARD
Sep 25, 20261,307.987 shares

Peers

ABBVAbbVie Inc.
$514.78B
AZNAstraZeneca PLC
$289.14B
BMYBristol-Myers Squibb Company
$127.02B
GILDGilead Sciences, Inc.
$207.00B
GSKGSK plc
$102.02B
JNJJohnson & Johnson
$664.95B
LLYEli Lilly and Company
$1273.77B
MRKMerck & Co., Inc.
$361.96B
Data last updated: Nov 9, 2026, 04:28 AM